Approval · Notice of Compliance 16960 · 2015
VYVANSE: Notice of Compliance 16960
Issued June 3, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16960
- Date
- June 3, 2015
- Company
- Shire Pharma Canada UlcToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Alternative administration with yogurt and orange juice, additional PK information and in vivo cytochrome P450 (CYP) drug interactions
- Therapeutic class
- Central nervous system stimulant
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VYVANSE | Not yet assigned | — |
Medicinal ingredients
- LISDEXAMFETAMINE DIMESYLATE 20 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 30 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 40 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 50 MG per CAP
- LISDEXAMFETAMINE DIMESYLATE 60 MG per CAP